NCT07312279Not yet recruiting
Study on the Efficacy of Temporal Interference Stimulation (TIS) for Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 31 Dec 2025
Brief summary (registry, in English)
The primary objective of this clinical study is to evaluate the therapeutic efficacy of Temporal Interference Stimulation (TIS), a non-invasive deep brain stimulation technique, in patients with Parkinson's disease, and to further investigate its potential mechanisms of action. Although TIS offers lower stimulation intensity and precision compared to conventional Deep Brain Stimulation (DBS), it possesses the distinct advantage of being non-invasive. This study utilizes TIS to explore different stimulation targets analogous to those used in DBS for Parkinson's disease, thereby providing valuable insights for subsequent DBS surgical interventions. The findings will contribute preliminary exploratory evidence regarding the application of non-invasive deep brain stimulation technology in the treatment of Parkinson's disease.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 12 Dec 2025
- Start date
- 30 Dec 2025
- Primary completion date
- 31 May 2026
- Lead sponsor
- Zhongnan Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT07312279
What you commit to
- Study type: Interventional
- Planned participants: 24
- From 30 Dec 2025 to the primary completion date, 31 May 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in other gait- or balance-related intervention training
Other illness
- Presence of other neurological disorders that may interfere with the study
- Mild or greater cognitive impairment (MoCA score ≤23)
- Orthopedic or other health conditions that may affect gait or balance
- History of antipsychotic, antidepressant, or other medications that may affect dopamine levels
- Other significant psychiatric history
- Contraindications including history of epilepsy, traumatic brain injury, or implanted metal devices in the brain or heart (e.g., stimulators, pacemakers)
- History of electroconvulsive therapy
Other
- Contraindications to MRI scanning, such as claustrophobia
- Physician-diagnosed cardiovascular risk factors for exercise.
Who the study is looking for
- Adult males or females aged 40 years or above;
- Diagnosed with idiopathic Parkinson's disease according to the UK Brain Bank Criteria, with onset after 40 years of age;
- Previous or current dopaminergic replacement therapy (e.g., levodopa) with good response; (4) Hoehn and Yahr (H\&Y) stage 1.5-2.5;
- Ability to walk independently without assistive devices for at least 5 minutes;
- Absence of severe freezing of gait (FOG);
- Disease duration ≥2 years since diagnosis, with stable clinical condition and ability to comply with study assessments and interventions;
- Stable medication dosage for at least 4 weeks prior to the study;
- Hoehn and Yahr (H\&Y) stage 1.5-2.5;
- Signed informed consent, with the participant or legal guardian capable of understanding and willing to participate in the study.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.